Literature DB >> 33692692

Network Pharmacology and Molecular Docking on the Molecular Mechanism of Luo-hua-zi-zhu (LHZZ) Granule in the Prevention and Treatment of Bowel Precancerous Lesions.

Cui Guo1,2, Xingdong Kang3, Fang Cao4, Jian Yang5, Yimin Xu1, Xiaoqiang Liu1,6, Yuan Li7, Xiumei Ma8, Xiaoling Fu1.   

Abstract

The Luo-hua-zi-zhu (LHZZ) granule has been widely used for the treatment of colorectal adenoma (CRA), which is a precursor of colorectal cancer (CRC). However, the active components of LUZZ and its mechanism of action against CRA have not yet been elucidated. This study was designed to investigate the effect of LHZZ on CRA and explore its pharmacological mechanisms. First, a total of 24 chemical constituents were identified in the 50% aqueous methanol extract of LHZZ granule based on the mass fragment patterns and mass spectral library using the high resolution UPLC-Q-TOF MS/MS system. Subsequently, based on a network pharmacology study, 16 bioactive compounds and 28 targets of the LHZZ associated with CRA were obtained, forming a compound-target network. Molecular docking tests showed tight docking of these compounds with predicted targeted proteins. The protein-protein interaction (PPI) network identified AKT1, CASP3, TP53 and EGFR as hub targets. The Kyoto Encyclopedia of Genes and Genomes pathway network and pathway-target-compound network revealed that the apoptosis pathway was enriched by multiple signaling pathways and multiple targets, including the hub targets. Finally, the reliability of the core targets was evaluated using molecular docking technology and in vitro studies. Our study indicated that the LHZZ particle has preventive and treatment effect on colorectal adenoma through multi-component, multi-target and multi-pathway.
Copyright © 2021 Guo, Kang, Cao, Yang, Xu, Liu, Li, Ma and Fu.

Entities:  

Keywords:  AKT1; LHZZ granule; colorectal adenoma; molecular mechanisms; network pharmacology

Year:  2021        PMID: 33692692      PMCID: PMC7938190          DOI: 10.3389/fphar.2021.629021

Source DB:  PubMed          Journal:  Front Pharmacol        ISSN: 1663-9812            Impact factor:   5.810


  5 in total

1.  Elucidating the anti-aging mechanism of Si Jun Zi Tang by integrating network pharmacology and experimental validation in vivo.

Authors:  Yang Yuan; Yanghuan Zhang; Runzi Zheng; Hongjun Yuan; Ruoyu Zhou; Shuting Jia; Jing Liu
Journal:  Aging (Albany NY)       Date:  2022-05-10       Impact factor: 5.955

2.  Network Pharmacology and Experimental Validation to Reveal the Pharmacological Mechanisms of Liuwei Dihuang Decoction Against Intervertebral Disc Degeneration.

Authors:  Huihao Zhang; Sai Yao; Zhiguo Zhang; Chengcong Zhou; Fangda Fu; Yishan Bian; Huan Luo; Yan Li; Shuxin Yan; Yuying Ge; Yuying Chen; Kunyu Zhan; Yanzhi Ge; Zuxiang Chen; Ming Yue; Xiaofeng Li; Weibin Du; Hongting Jin; Peijian Tong; Hongfeng Ruan; Chengliang Wu
Journal:  Drug Des Devel Ther       Date:  2021-12-02       Impact factor: 4.162

3.  Integration of Network Pharmacology and Experimental Validation to Explore the Pharmacological Mechanisms of Zhuanggu Busui Formula Against Osteoporosis.

Authors:  Huihao Zhang; Chengcong Zhou; Zhiguo Zhang; Sai Yao; Yishan Bian; Fangda Fu; Huan Luo; Yan Li; Shuxin Yan; Yuying Ge; Yuying Chen; Kunyu Zhan; Ming Yue; Weibin Du; Kun Tian; Hongting Jin; Xiaofeng Li; Peijian Tong; Hongfeng Ruan; Chengliang Wu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-28       Impact factor: 5.555

4.  Potential Therapeutic Targets of Rehmannia Formulations on Diabetic Nephropathy: A Comparative Network Pharmacology Analysis.

Authors:  Kam Wa Chan; Kam Yan Yu; Wai Han Yiu; Rui Xue; Sarah Wing-Yan Lok; Hongyu Li; Yixin Zou; Jinyuan Ma; Kar Neng Lai; Sydney Chi-Wai Tang
Journal:  Front Pharmacol       Date:  2022-03-21       Impact factor: 5.810

5.  Exploring the Mechanism of Action of Canmei Formula Against Colorectal Adenoma Through Multi-Omics Technique.

Authors:  Cui Guo; Xiaoqiang Liu; Yimin Xu; Xinyue Han; Runnan Xie; Xiangxue Meng; Yuan Li; Tongyu Chen; Zhihong Cheng; Xiaoling Fu
Journal:  Front Cell Dev Biol       Date:  2021-11-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.